INTRODUCTION

Background
There are an estimated 346 million people with diabetes worldwide. Type 2 diabetes mellitus (T2DM) is the most common, accounting for 90% of the diabetic population [1] . Unlike people with type 1 diabetes, who require insulin, people with T2DM can initially manage their condition without pharmacological intervention. However, the natural history of T2DM, characterized by progressive decline in beta cell function, results in an inevitable need for multiple pharmacotherapies including oral antidiabetic drugs (OADs), insulin, or both, in order to optimize blood glucose control [2] . Indeed, over the course of the UK Prospective Diabetes Study (UKPDS),[50% people treated with sulfonylureas required additional insulin to maintain fasting plasma glucose levels \6 mmol/L, within 6 years of T2DM diagnosis [3] .
There is a growing emphasis on insulin management. Insulin initiation early within the natural history of T2DM is now endorsed by professional bodies including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [4] .
The growing prevalence of T2DM and data suggesting a reduction in mortality in people with T2DM indicate that the use of insulin for the management of glucose control in people with T2DM will continue to rise [5] .
Accordingly, there is widespread interest in evaluating the safety, efficacy, costeffectiveness, and affordability of alternative insulin treatments. A number of insulin products are available that address variability in patient phenotypes, preference, and response to treatment. Preparations are available that more closely mimic normal insulin production (short-acting) or provide a continuous supply of insulin over a longer time period (intermediateand long-acting).
Recent Evidence
The intermediate-acting human isophane insulin (NPH) and the long-acting analog insulins glargine and detemir have been the subject of recent reviews that have brought into question the clinical benefits and economic value of long-acting insulin analogs compared to human insulin [6] [7] [8] . These reviews suggest that insulin analogs and NPH are similarly effective in terms of glycemic control; however, clinical and economic value should also be assessed from the perspective of other clinical endpoints, including hypoglycemia [9] . Hypoglycemia is a recognized consequence of intensification of glucose control [10] [11] [12] . In people with T2DM receiving insulin therapy for \2 years, nearly 50% of patients reported recurrent symptomatic hypoglycemia, while 20% of patients reported at least one episode of severe hypoglycemia [13] . Hypoglycemia has significant clinical and economic implications, thus an increase in the rate of hypoglycemia with human compared to analog insulin may exert significant health economic implications [14] [15] [16] [17] . Further, it is important to remember that these reviews were based on the results of randomized controlled trials that evaluated highly selected patient populations under tightly controlled conditions [6, 7] . [18] .
Hence, from the perspective of informing public spending decisions, an evaluation of acquisition costs alone does not provide a true sense of the total economic consequences associated with insulin choice.
Aims
The purpose of this study was to extend the analysis of human versus analog basal insulin to illustrate the limitations of analyses that, we argue, improperly restrict the decision context to the results of randomized trials and drug acquisition cost. We aim to inform questions surrounding the ''value for money'' associated with the use of human and long-acting analog insulins.
MATERIALS AND METHODS
Literature Review
The authors adopted a societal perspective by considering the direct and indirect costs associated with T2DM. The authors developed a prevalence-based budget impact assessment model that characterizes components of resource utilization (costs) associated with the periods surrounding insulin initiation, defined by the need for resources used in the Data from the reviewed studies was summarized for human insulin and long-acting analog insulins. The results for the human and analog insulins were stratified according to whether they were direct costs: hypoglycemiarelated, medications (diabetes or other), medical services (diabetes or other); or indirect costs.
Analytical Approach
Data from the included studies was summarized for each direct and indirect resource category associated with the management of T2DM and use of basal insulin. Data for total expenditure and diabetes-related medication expenditure were adjusted to 2011 values and standardized to British pounds sterling (GBP) in references to temporal changes in country exchange rates [19] . A quasi meta-analysis was undertaken whereby the point estimates from each study were weighted by the proportion of subjects in 
RESULTS
Literature Review
The literature review identified 161 studies and a variety of resource utilization categories (Table 1) . Of the reviewed studies nine were considered relevant (Tables 2, 3 ) [14, [21] [22] [23] [24] [25] [26] [27] [28] . All studies were industry-sponsored. Details of the included studies including number of people, treatment setting, study year, study design and follow-up period, mean age, and primary objective, are reported in Table 4 [14, [21] [22] [23] [24] [25] [26] [27] [28] .
Budget Impact Assessment
In the budget impact assessment, total diabetesrelated medication expenditure per person was 15% lower each year with human insulin versus analog insulin. Once all relevant costs were factored into the analysis, the total annual expenditure associated with human insulin was 8% higher at an individual level compared to analog insulin, and this includes the cost of diabetes-related medications.
The authors estimate that for the UKprevalent population of T2DM, patients total and diabetes-related medication expenditure is £3,901 and £397 million, respectively, each year. The authors estimate that medication acquisition cost savings in the order of £26 million a year might be achieved if all analog insulin users converted to human insulin, but that any savings in medication acquisition cost would be consumed/offset by the estimated increase in overall treatment costs to individuals and the NHS of £284 million each year.
Across modeled scenarios whereby there is a positive utilization of each insulin type, a 10% increased use of human insulin and a proportional decrease in the use of long-acting analog insulin would save the NHS around £5 million each year on drug acquisition cost, but the net overall cost to the NHS would increase by £34 million each year (Table 5 [1, 6, 8, 29] , Fig. 1 ). For scenarios ranging from a 10% to 40% increased use of human insulin and an equivalent reduction in the use of analog insulins from current levels, this equates to a potential saving between £5 million and £23 million each year on drug acquisition cost, but the net overall cost to the NHS would increase by £34 million to £136 million each year.
DISCUSSION
In the management of T2DM a complicated picture arises when considering the relationship between overall clinical benefit (for example, glycemic control vs. hypoglycemia), treatment options (comparative effectiveness), and 
Comparison to Other Studies
In the UK it has been estimated that around £3.5 billion is spent on diabetes each year [31, 32] . Looking across the various levels of a health service and more broadly into society, the authors estimate the total expenditure associated with T2DM to be £3.9 billion each year. Our analysis of human and analog insulins suggests that total annual diabetes-related medication expenditure is £397 million.
This analysis extends recent reports of the value for money relationship between human and analog insulins by delineating medication acquisition costs and total costs associated with Weighted average across three treatment settings which were defined as the severe event being treated and managed by a ' 'family member/friend' ', ' 'community healthcare worker' ' or ' 'in hospital' ' Historical exchange rates used for conversion [19] GBP British pounds sterling, GDP gross domestic product, LL lower limit, Weighted average across three treatment settings which were defined as the severe event being treated and managed by a ' 'family member/friend' ', ' 'community healthcare worker' ' or ' 'in hospital' ' Historical exchange rates used for conversion [19] GBP British pounds sterling, GDP gross domestic product, LL lower limit, OADs oral antidiabetic drugs, i.e., standard deviation (SD) or standard error (SE)]. Thus it was not possible to estimate the statistical heterogeneity between studies and therefore their similarity. In using a weighted average of point estimates, with study size as the weighting factor, we are able to quantify the cost implications associated with insulin use, which may be useful to other researchers and decision makers. The authors do stress, however, that caution should be exercised when interpreting their findings given that there may be important differences between the combined studies; the table of study details (Table 4 ) may be useful in addressing this limitation. Thirdly, the nature of study sponsorship (i.e., industry-sponsored research) may impact the results of an individual study and hence the synthesis of estimates across studies. One approach in addressing this type of bias is to exclude studies whose sponsorship may directly or indirectly affect study findings.
The studies identified from the current literature review were all industry-sponsored. On this basis, the authors could not exclude industry-sponsored studies. The authors note this as a limitation of the available data and a potential source of bias in their study estimates.
Cost Drivers
Since the primary therapeutic advantage of the analog insulins relates to a reduction in hypoglycemia [33] , potential cost drivers in this context include excess blood glucose monitoring costs [14] , additional costs related Estimates based on 2.8 million people in the UK with diabetes [1, 8] , with 90% of people with type 2 diabetes, [1] and 26-27% of these people using insulin [29] GDP gross domestic product a Average prescription utilization in the UK from 2000 to 2009 [6] . Data are adjusted for study size and variation in GDP per country (see ' 'Materials and Methods' ' section)
to suboptimal insulin dosing and therapy nonadherence consequent upon hypoglycemia [34] , and the costs associated with hypoglycemia-associated hospitalization [15, 35, 36] . In explaining why the more expensive long-acting insulin products can be cost saving in terms of total expenditure, the authors speculate to the association between the use of analog insulins and cost offsets associated with a reduction in hypoglycemic events and reduced frequency of injections from twice to once daily.
Hypoglycemia represents a major clinical barrier to achieving glycemic control in people with diabetes and has a major economic impact on overall healthcare spending. Over 30% of people with T2DM treated with insulin experience symptomatic hypoglycemia [37] , while data from recent mega trials evaluating the potential outcome benefit associated with intensification of glucose control has demonstrated an association between severe hypoglycemia and an increased risk of diabetes-related complications [38] . Furthermore, a recent retrospective observational analysis of [860,000 people with T2DM which examined the relationship between hypoglycemic events and acute cardiovascular events over a 2-year period demonstrated that after controlling for multiple confounders, patients with documented outpatient hypoglycemic events had a 79% higher regression-adjusted odds [odds ratio 1.79; confidence interval (CI) 1.69-1.89] of acute cardiovascular events than patients without documented hypoglycemic events. In addition, those patients who experienced hypoglycemia incurred twofold greater health-related expenditure [15] .
Further studies are required to confirm these findings.
Hypoglycemia results in significant resource utilization form a healthcare perspective. This concept is supported by the fact that hypoglycemia is the primary diagnosis resulting in 14,437 hospital admissions in the UK between 2009 and 2010, accounting for a total bed occupancy of 76,569 days [39] .
Hypoglycemia also has a significant impact on the quality of life of people with diabetes as well as therapy adherence. Symptomatic hypoglycemia is associated with reduced therapy adherence, treatment satisfaction, and A reduction in the frequency of nocturnal hypoglycemia is one the key advantages of the insulin analogs (insulin detemir and insulin glargine), compared to human insulin. This represents a major consideration when considering the value for money proposition of these insulin preparations since almost 50% of all episodes of severe hypoglycemia occur at night during sleep [43] . Nocturnal hypoglycemia results in significant detrimental effects on mood and wellbeing the following day and has the greatest socioeconomic consequences from the perspective of reduced productivity and lost time at work, and represents a particular barrier to optimal insulin dose titration [14, 43, 44] . In addition, nocturnal hypoglycemia has been causally associated with acute sudden death [45] , while recurrent nocturnal hypoglycemia is linked to the development of hypoglycemia unawareness, which in turn is associated with a higher rate of severe hypoglycemia [46] . Differences in rates of hypoglycemia between human and analog insulins were conflated in the results of the individual studies that informed our cost analysis. In the discussion the authors have only speculated to theoretically plausible clinical explanations of cost drivers. As such, we cannot directly attribute our expenditure estimates to different cost drivers. Instead we have used a linked evidence approach [47] to highlight the likely role of hypoglycemia as an overall cost driver and explanation for our key finding that human insulin is, on balance, likely to be more expensive than analog insulins.
CONCLUSIONS
It is difficult to gain a sense of the extent of expenditure made by individuals and governments in managing T2DM. The authors find that direct and indirect expenditure is significant. Diabetes-related medication expenditure is generally lower in users of human insulin compared to users of longacting analog insulin. Overall, though, the use of analog insulins was cost saving compared to human insulin. These productivity gains may be related to fewer hypoglycemic events.
The value for money of human insulin and analog insulins does not rest at medication acquisition costs alone. Governments and decision makers should consider that total healthcare expenditure will not necessarily decrease when decisions are based solely on the use of cheaper products. By factoring in the clinical benefits of insulin analogs in contrast to their higher costs, we estimate that a paradigm shift towards increased use of human insulin and decreased use of analog insulin would on average increase the net societal cost of managing insulin-treated patients with T2DM.
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